Conclusions: Despite awareness of their HCV infection, and their desire to get treated PWID do not routinely seek medical care. Barriers such as inaccessible medical care, unfamiliarity with available resources, and concerns regarding treatment side effects have been identified. Organized and targeted community events such as PPCs increase likelihood of reaching out to marginalized and high risk inner city populations to address these barriers in a systematic way. Disclosures: Brian Conway – Advisory Committees or Review Panels: Vertex Pharmaceuticals, Merck, Boehringer

Ingelheim, Jannsen Pharmaceuticals; Grant/Research Support: Vertex Pharmaceuticals, Merck, Boehringer Ingelheim, Jannsen Pharmaceuticals, AbbVie, Gilead Sciences, Gilead Sciences The following people have nothing to disclose: Behroz Rashidi, Shawn Sharma, Syune Hakobyan, BMN 673 molecular weight Osamah Alenezi,

Amy Hung, Kevin Yen, Xinyang Huang, Harout Tossonian Renal dysfunction has been reported in Cabozantinib in vitro patients on antiviral therapy containing protease inhibitors (PI) bocepravir and telaprevir. Diabetes and hypertension were risk factors and associated with eGFR decline to <60mL/min at treatment week 12 (TW12). Also, an eGFR of <60mL/min was associated with lower haemoglobin (Hb) levels at TW12. Hypothesis: Serum NGAL has been reported as a biomarker for renal tubular injury and suppressant of red blood cell production, while Cystatin C a biomarker for glomerular function. Thus can NGAL and Cystatin C predict renal function decline and anaemia severity in patients on PI containing antiviral therapy. Method: Thirty-three patients with HCV genotype 1 undergoing PI based antiviral therapy had serum NGAL and Cystatin C measurements at specific time points: treatment initiation (TW0), Glycogen branching enzyme TW12, end of treatment (EOT) (median 41 weeks) and 24 weeks post treatment (FUW24),

using commercial ELISA kits. Creatinine, eGFR and Hb measurements were also made at these points. Statistical analysis was performed using SPSS and median values are expressed. Results: Of the thirty-three patients (median age 50.32 years), twenty-two had cirrhosis with nine having renal disease risk factors (diabetes and hypertension). The remaining eleven were neither cirrhotic nor had renal risk factors. Four cirrhotics with and five without renal risk factors were treated with telaprevir, and the remainder received bocepravir. The SVR rates were comparable between the telaprevir and bocepravir groups (75% and 70.5% respectively). Serum NGAL levels showed no significant differences based on PI, sustained viral response or level of fibrosis. However, in cirrhotics regardless of the PI, a statistically significant rise in NGAL levels from TW0 until EOT with subsequent resolution was observed. Interestingly, TW0 NGAL levels >70 ng/ ml were associated with > 4g/dl Hb decline at TW12 (PPV 89%), necessitating erythropoetin (EPO) instigation. Cystatin C levels were higher at TW0 in cirrhotics vs.